The “smart pill” market is expected to nearly quadruple in value to $3 billion by 2025, according to Grand View Research. Driving this growth is an increasing demand for minimally-invasive procedures, as well as better patient monitoring capabilities. There are a number of players in the pharmaceutical and medtech arenas looking to stake a claim […]
Medtronic
Semma Therapeutics closes $114m round to advance cell therapy for Type I diabetes
Semma Therapeutics has closed an oversubscribed $114 million Series B round to help fund the development of its encapsulated stem cell-derived islet therapy for Type I diabetes. The Cambridge, Mass.-based company reported that it plans to use the newly-acquired funds to bring its cell therapy through clinical proof-of-concept studies, as well as explore other regenerative […]
Medtronic retools SynchroMed II infusion pump
Medtronic (NYSE:MDT) said this month that it won approval for a change to its problematic SynchroMed II implantable drug infusion pump designed to address motor shaft wear issues. The Fridley, Minn.-based medical device titan said the change is aimed at improving the long-term rate of non-recoverable motor stall in the SynchroMed II devices, estimating that pump […]
JDRF touts win after Anthem decides to cover artificial pancreas systems
JDRF said today it successfully persuaded Anthem to cover artificial pancreas systems, after meeting the health insurer as part of its Coverage2Control campaign. America’s 25 largest health insurers now cover Medtronic‘s (NYSE:MDT) MiniMed system, according to the organization. “This is a great victory for the T1D community. By taking this tremendous step, Anthem is giving […]
How DarioHealth turned the smartphone into a user-friendly glucose monitor
When DarioHealth (NSDQ:DRIO) CEO Erez Raphael looks at the medical device world, he sees solutions that were designed by healthcare professionals and doctors – and this presents a stark contrast with the consumer device industry, he pointed out. “We have seen there are a lot of cases, most of the cases in the industry, where the […]
TCT 2017: Medtronic & OrbusNeich evaluate shortening dual anti-platelet therapy with drug-eluting stents
At this year’s Transcatheter Cardiovascular Therapeutics meeting, companies presented work comparing shortened durations of dual anti-platelet therapy with the standard 1-year regimen in patients treated with a drug-eluting stent. Among those companies were Medtronic (NYSE:MDT) and OrbusNeich. Here’s a look at what they found. Medtronic’s DAPT-STEMI trial Yesterday, investigators presented data from Medtronic’s independently-run DAPT-STEMI trial, […]
Medtronic touts economic analysis of CGM use in Type II diabetes
Medtronic (NYSE:MDT) touted data today from an economic analysis evaluating the use of professional continuous glucose monitoring in people with Type II diabetes. Data from the study, which the company called the first of its kind, showed significant cost avoidance to the healthcare system when CGM was used during a therapy change or when used […]
JDRF wants to expand access to DIY diabetes tech – here’s how
As companies race to develop the first fully-automated insulin delivery system, a group of tech-savvy patients are hacking their own artificial pancreas systems. And industry is just starting to take notice of this highly motivated grassroots movement. “They want more choice. They want more freedom. And, essentially, they want it now,” JDRF research director Dan […]
Surmodics goes head-to-head with Medtronic’s drug-coated balloon in pivotal trial
Surmodics (NSDQ:SRDX) announced today that the first patient was enrolled in a pivotal clinical trial evaluating its SurVeil drug-coated balloon. The 446-patient trial is designed to compare the company’s SurVeil device to Medtronic‘s (NYSE:MDT) In.Pact Admiral drug-coated balloon as a treatment for peripheral artery disease in the upper leg. “Based on the preclinical and early feasibility study […]
Insulet looks to lure Animas users
Just days after Johnson & Johnson (NYSE:JNJ) revealed that it plans to shut down its 410-worker Animas insulin pump subsidiary, Insulet (NSDQ:PODD) said it would offer existing Animas insulin pump users a free trial of the company’s Omnipod system. Insulet’s Welcome Program includes a free Omnipod tubeless insulin delivery system, built-in blood glucose meter and 30 days […]
